Breast Cancer
CDK inhibitors in breast cancer Learning Zone
CDK4/6 inhibitors in breast cancer
Are you familiar with the clinical trial evidence that could help you to select the best cyclin dependent kinase 4/6 (CDK4/6) inhibitor for your metastatic breast cancer patient?
CDK4/6i eLearning module
EACCME®-accredited, 1 CME credit
Publication digest
Concise infographic summaries on early breast cancer stratification
Future breast cancer care: ESMO Breast Cancer 2024
Read about the latest updates in breast cancer research presented at ESMO Breast Cancer 2024, from the experts who attended.
ASCO 2024 A high-level overview
From ASCO 2024, read Dr Ben Gallarda’s overview of ASCO’s commitment to palliative care, artificial intelligence, and coordination with organizations.
Abemaciclib: a newcomer in the treatment of HR+/HER2− early breast cancer
Abemaciclib, a CDK4/6 inhibitor, is the first adjuvant in 16 years to be added to endocrine therapy for HR+/HER2− early breast cancer and the first of its class to receive FDA and EMA approval for this indication.
Symposium on refractory multiple myeloma, COMy 2023
Watch our expert panel discussion on the management of relapsed and refractory multiple myeloma (RRMM) in older and frail adults.
How can poor-quality clinical trials impact clinical decision-making?
Explore why a cautious approach is warranted when interpreting trial results.
of interest
are looking at
saved
next event